Pharmafile Logo

From Genetic Puzzles to Precision Therapeutics

December 23, 2025 |  

How was a new rare disease discovered through Singapore’s Undiagnosed Disease Program? And how will technology allow us to change how we discover rare diseases in the future? Read more to find out.

soumya headshot

A/Prof Saumya Jamuar
Senior Consultant, Genetics service, KK Women’s and Children’s Hospital
Director, SingHealth Duke-NUS Institute of Precision Medicine
Lead Principal Investigator, Singapore Undiagnosed Disease Programme

christy headshot

S.Christy Rohani-Montez
Senior Director of Clinical Strategy
Rare Disease Education Lead
Medscape Education

Christy: I’m so excited to be in Singapore speaking with you Saumya, about Singapore’s Undiagnosed Disease Program.

Can you tell me first a little about yourself and how you got into rare diseases?

Saumya: Sure, so I’m a pediatrician and clinical geneticist at KK Women’s and Children’s Hospital. Since I was young, I’ve loved puzzles. To me, a patient with a rare disease is a puzzle with multiple pieces that need to be put together. I saw that as I was training in pediatrics where I would see patients being managed by the cardiologist, the neurologist, the gastroenterologist, and more. They would each be focusing on their specialty, and I found myself taking a step back and asking, “Hey, are these issues all connected in some way?”

That’s where I realized rare diseases play a part, because these rare diseases tend to connect the different organ systems and specialties. That passion for puzzle-solving got me into this field. What propelled it further was the pediatric setting, because the stakes are much higher for children. Once you get an answer and have that “aha” moment where it all makes sense, that brings so much joy into the work and accelerates the desire to continue.

Christy: Tell me about the condition named after you and the program behind it?

Saumya: I established Singapore’s undiagnosed disease program, which we call BRIDGES (Bridging Research Innovations for the Diagnosis of GEnetic Diseases in Singapore), to connect patients with genomic technologies. One of our first major successes came when 2 siblings were referred to my clinic with epilepsy and developmental delays where their speech was more affected than their motor skills. Standard tests were all negative, so we enrolled them in BRIDGES where we performed whole exome sequencing with our collaborators at A*STAR (Singapore’s Agency for Science, Technology and Research), and identified a novel variant in a gene called UGDH.

The product of UGDH is an enzyme that’s critical for building the structural matrix of the brain. You can imagine if the matrix isn’t there, the circuitry is missing. The brain is just a lot of wires, and if the wires aren’t connected properly, that’s when things go haywire. This led to the phenotype we were seeing: epilepsy and developmental delays. We reached out to our global network and found 18 other families with similar features and variants in the same gene. Through lab work with patient cells and cerebral organoids, we proved this was the cause and had discovered a new disease, which was named after me, the Jamuar Syndrome, and is also known as UGDH-related disorder.

Christy: What has the BRIDGES program achieved since then?

Saumya: We have successfully recruited over 850 families over the last decade, and have steadily improved our diagnostic yield from about 30% to 49%, comparable to international benchmarks. Beyond the diagnosis itself, the results have a profound impact. All families receive precise genetic counseling, and in 80% of cases, we can stop the “diagnostic odyssey” of endless tests.

Most importantly, in 27% of our diagnosed cases, there has been a direct impact on each patient’s medical management. For example, one child was hospitalized for her entire first year of life with multiple infections. An exome sequence revealed an immune dysregulation that could be treated with a bone marrow transplant. She finally went home. This was our first real foray into precision therapeutics, where knowing the exact genetic pathway allowed us to provide a targeted, life-changing treatment.

Christy: What are your long-term goals for the future?

Saumya: We are focused on 2 key areas. Firstly, we are expanding access to genomics to underserved regions in Southeast Asia through our Genomics for Kids in ASEAN initiative, generously supported by the Temasek Foundation.

Secondly, we are looking ahead to the next decade, which will be all about therapeutics. Today, only 5% of rare diseases are treatable. To change that, we are developing a therapeutic platform. Instead of a slow, single-gene, single-disease approach, we want to categorize conditions based on their functional outcome—for example, is the protein absent or is it dysfunctional? Then, we can match the problem to a class of solutions (like gene replacement or gene editing) and a delivery system that can target the affected organ. This creates a systematic, 3-dimentional matrix to treat many more patients at a much faster rate and probably at lower costs.

Christy: Your work is incredible, thanks so much for speaking with me today!

For more information, please contact Christy Rohani Montez PHD –
srohani@medscape.net

About Medscape Education

Medscape Education (medscape.org) is the leading destination for continuous professional development, consisting of more than 30 specialty-focused destinations offering thousands of free CME and CE courses for physicians, nurses, and other healthcare professional

This content was provided by Medscape Education

Company Details

 Latest Content from  Medscape Education 

Empowering Women in Health Care Through Education  

In a bold stride toward empowering women in health care, Medscape proudly announces its sponsorship of the highly anticipated Women in Medicine Summit, September 13-14, 2024 in Chicago, Illinois. This...

Leading the Way at ESC 2024

Anticipation is building at Medscape Education as the team prepares for the ESC 2024 Congress. We are excited to announce a significant presence during the congress including a booth (#H500)...

Always Be in a Growth Mindset: Chief Strategy Officer Christina Hoffman’s Return to Her Education Roots

Medicine is always changing, and the career of Medscape Education’s Chief Strategy Officer, Christina Hoffman, is no exception. The 17-year Medscape veteran recently said goodbye to her role as leader...

Medscape Education Showcases Unprecedented Achievements at EHA 2024

Medscape Education is proud to share its monumental success at the EHA 2024 Congress. Our continued commitment to patient-centric medical education was evident throughout the event, with notable achievements and...

Reaching Women Where They’re At: Setting Up a Safe Space for HIV Prevention Conversations

“I always enjoyed solving problems and putting puzzles together,” says Harmony Garges, MD, CMO at ViiV Healthcare and a pediatric infectious disease specialist. “So for me, infectious disease was a...

Medscape Education Demonstrates Strong Education Outcomes at the American Diabetes Association 2024 Conference

Medscape Education presented seven scientific posters at this year’s American Diabetes Association (ADA) conference in Orlando, Florida. These posters highlighted the outcomes of Medscape Education’s continuing medical education programs, which...

Stemming the Flow–Medscape Presents at HLTH Europe

Medscape Education will be attending HLTH Europe from June 17-20. Be sure to drop by our booth to participate in our survey and enjoy exciting giveaways. Additionally, Dr. John Whyte,...

Medscape Education to Emphasize the Role of Education in Digital Therapeutics at DTA Summit

As a leader in medical education and proud sponsor of the 2024 Digital Therapeutics Summit, Medscape is excited to announce that Medscape Education’s Chief Strategy Officer, Christina Hoffman, will be...

Medscape Oncology to Make a Significant Impact at ASCO 2024

ASCO is one of the biggest conferences of the year for Medscape Oncology, and the team is ready to make an impact in Chicago. They’ll be manning booth #26030, where...

Medscape Oncology Launches Inaugural Medscape Fellows Program at ASCO 2024

Medscape Oncology is excited to announce the launch of the first-ever Medscape Fellows Program at the 2024 ASCO meeting in Chicago, Illinois. This groundbreaking program aims to nurture young oncology...